Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer

Cancer

Volumn 83, Issue 6, 1998, Pages 1136-1141

  Bajetta, Emilio ^a   Biganzoli, Laura ^a   Carnaghi, Carlo ^a   Di Bartolomeo, Maria ^a   Spagnoli, Ivo ^a   Cassata, Antonio ^a   Galante, Emanuele ^a   Mariani, Luigi ^a   Stampino, Corrado Gallo ^b   Buzzoni, Roberto ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ROCHE MILANO RICERCHE   (Italy)

Author keywords

Breast carcinoma; Chemotherapy; Doxifluridine; Elderly; Fluoropyrimidine

Indexed keywords

ANTINEOPLASTIC AGENT; DOXIFLURIDINE; FOLINIC ACID;

AGED; AGING; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; GERIATRIC PATIENT; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTIDOTES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; FLOXURIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; METHOTREXATE; NEOPLASM STAGING;

EID: 0032530811     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1136::AID-CNCR12>3.0.CO;2-6     Document Type: Article

References (26)

1. Muss HB. Breast cancer in older women. Semin Oncol 1996; 23(Suppl 2):82-8.
2. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 1993;85:1580-4.
3. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304: 10-5.
4. Gelman RS, Taylor SG. Cyclophosphamide methotrexate and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984;2:1404-13.
5. Frei E, Canellos GP. A critical factor in cancer chemotherapy. Am J Med 1980;69:585-94.
6. Christman K, Muss HB, Case LD, Stanley V. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association Experience. JAMA 1992;268:57-62.
7. Goldhirsch A, Gelber RD, Castiglione M, Prince KN, Rudenstam CM, Lindtner J, et al. The best available adjuvant treatments are within the framework of clinical trials. International Breast Cancer Study Group. Isr J Med Sci 1995;31: 144-54.
8. McKenna RJ. Clinical aspects of cancer in the elderly, Treatment decisions, treatment choices, and follow-up. Cancer 1994;74(Suppl 7):2107-17.
9. Alberto P. Phase II study of an oral combination of doxifiuridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer. Ann Oncol 1993;4:423-5.
10. Hurtelaup P, Armand JP, Coppelaere P, Cappelaere P, Metz R, Kerbrat P, et al. Phase II clinical evaluation of doxifluridine. Cancer Treat Rep 1986;70:731-7.
11. Alberto P, Jungl WF, Siegenthaler P, Mermillod B, Obrecht JP, Decoster G, et al. A Phase II study of doxifluridine in patients with advanced breast cancer. Eur J Cancer Clin Oncol 1988;24:565-6.
12. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1994;12:2296-300.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
14. Appendix A: grading of toxicity. In: Wittes RE, editor. Manual of oncologic therapeutics. Philadelphia: J.B. Lippincott Co., 1981:445-8.
15. Simon R. Optimal two-stage design for phase II clinical trials. Control Clin Trials 1989;10:1-10.
16. Atkinson EN, Brown BW. Confidence limits for probability of response in multistage phase II cancer clinical trials. Biometrics 1985;41:741-4.
17. Ganz PA, Schag CC, Heinzich RL. The psychosocial impact of cancer on the elderly. A comparison with younger patients. J Am Geriatr Soc 1985;33:429-35.
18. Nerenz DR, Love RR, Leventhal H, Easterling DV. Psychosocial consequences of cancer chemotherapy for elderly patients. Health Serv Res 1986;20:961-76.
19. Samet J, Hunt WC, Key C, Humble CG, Goodwin JS. Choice of cancer therapy varies with age of patients. JAMA 1986; 255:3385-90.
20. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989;7:890-9.
21. Loprinzi CL, Ingle JN, Schaid DJ, Buckner JC, Edmonson JH, Allegra CJ. 5-fluorouracil plus leucovorin in women with metastatic breast cancer. A Phase II study. Am J Clin Oncol 1991;14:30-2.
22. Loprinzi CL. 5-fluorouracil with leucovorin in breast cancer. Cancer 1989;63:1045-7.
23. Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Gabriel NH. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med 1996;156:882-8.
24. Repetto L, Simoni C, Venturino A, Biancardi V, Gasco M, Campora E. Mitoxantrone in elderly women with advanced breast cancer: a Phase II study. Anticancer Res 1995;15:2297-300.
25. Monfardini S, Chabner B. Joint NCI-EORTC Consensus Meeting on neoplasias in the elderly. Eur J Cancer 1991;27: 653-4.
26. Cascinu S, Del Ferro E, Catalano G. Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol 1996;19:371-4.